Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now

Corporate Profile

Investor Presentation

Read Now

highlightbg1

Our Pipeline

Learn More
highlightbg2
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

June 11, 2021

BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

June 11, 2021

BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

June 9, 2021

Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

Key Metrics

Key Metrics

  • 5,400+

    Employees

  • 1,600+

    Clinical team

  • 5

    Continents

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept